Ono Pharmaceutical (4528) · RiskMitigated
Borrowing and financial covenant risks associated with the Deciphera acquisition
First written in FY2025. 1 of 2 entries say "Mitigated", first in FY2026. Latest entry: FY2026.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Risk of repayment obligations on borrowings due to breach of financial covenantsA theme 163 companies write about · 164 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2017: 8 of 54 companies on the "Worse" side.
52 other companies' latest entry also says "Mitigated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 163 companies compared. The sentences above are computed from all 163.Full recordFilings, disclosures and news, newest first
- FY2026MitigatedAnnual report
「Balance at period-end: ¥105 billion Repayment date: end of September 2029…If any of the financial covenants below is breached, all obligations under this agreement may become immediately due and payable.」
The balance of the term loan related to the acquisition of Deciphera decreased from ¥135 billion to ¥105 billion. The repayment date at the end of September 2029 and the financial covenants relating to the maintenance of net assets and operating losses remain in place. - FY2025First statedAnnual report
「Balance at period-end: ¥135 billion Repayment date: end of September 2029…If any of the financial covenants below is breached, all obligations under this agreement may become immediately due and payable.」
The company raised an unsecured ¥135 billion term loan to fund the acquisition of Deciphera, with financial covenants relating to the maintenance of net assets and operating losses identified for the first time as an independent risk.